Daniel Holmes, MD
Urology · Kansas City, MONPI 1720038227
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (40.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 69.2% of it on its own, with 40 other manufacturers making up the rest. Reporting peaked in 2019 at $6,653 and has fallen 90.5% since, to $635 in 2025.
Across 112 payments — averaging $83.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Mevion_medical_systems_inc$309
- Conmed Corporation$291
- Johnson & Johnson$263
- Teleflex LLC$168
- Boston Scientific$147
- plus $2K from 35 others
What the payments were for
- Travel & lodging$2,70229%
- Food & beverage$2,89331%
- Education$3,78540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 17 | $6,488 |
| Mevion_medical_systems_inc | 1 | $309 |
| Conmed Corporation | 2 | $291 |
| Johnson & Johnson | 11 | $263 |
| Teleflex LLC | 1 | $168 |
| Boston Scientific | 3 | $147 |
| AbbVie | 9 | $146 |
| Novartis | 1 | $134 |
| Procept Biorobotics Corporation | 2 | $131 |
| Astellas Pharma US Inc | 6 | $113 |
| Blue Earth Diagnostics | 5 | $96 |
| Endo USA, Inc. | 4 | $90 |
| Dendreon Pharmaceuticals LLC | 3 | $82 |
| Olympus America Inc. | 4 | $77 |
| Urogen Pharma, Inc. | 3 | $72 |
| Myriad Genetic Laboratories, Inc. | 4 | $72 |
| Antares Pharma, Inc. | 4 | $63 |
| Pfizer | 3 | $54 |
| Sumitomo Pharma America, Inc. | 2 | $52 |
| Rochester Medical Corporation | 2 | $50 |
| Tolmar, Inc. | 2 | $48 |
| Azurity Pharmaceuticals, Inc. | 2 | $39 |
| Urovant Sciences Inc | 2 | $35 |
| AstraZeneca | 1 | $35 |
| Halozyme Inc | 2 | $32 |
| Axogen | 1 | $31 |
| Immunitybio, Inc. | 1 | $30 |
| Progenics Pharmaceuticals, Inc. | 1 | $25 |
| Smith+Nephew | 1 | $22 |
| Convatec Inc. | 1 | $20 |
| Biotissue Holdings Inc. | 1 | $17 |
| Verity Pharmaceuticals Inc. | 1 | $17 |
| Accord Healthcare, Inc. | 1 | $16 |
| Coloplast | 1 | $16 |
| Amgen | 1 | $15 |
| Therapeuticsmd, Inc. | 1 | $15 |
| Axonics, Inc. | 1 | $14 |
| Laborie Medical Technologies Corp. | 1 | $14 |
| Sanofi | 1 | $14 |
| Merck | 1 | $14 |
| Ambu Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$6,265
- PTS250$309
- AIRSEAL$291
- UroLift$168
- PLUVICTO$134
- Erleada$123
- AQUABEAM SYSTEM$120
- LithoVue$104
How this compares
$9,380 in reported general payments places this provider in the 80th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 101 | $123,484 |
| MyrbetriqMirabegron | 88 | $82,511 |
| Tamsulosin Hcl | 905 | $14,297 |
| Finasteride | 834 | $11,341 |
| Solifenacin Succinate | 42 | $3,345 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 90 | $2,212 |
| Tolterodine Tartrate ErTolterodine Tartrate | 21 | $1,385 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 82 | $1,232 |
| Silodosin | 14 | $1,157 |
| Trospium Chloride | 22 | $919 |
| Dutasteride | 25 | $730 |
| Doxycycline Hyclate | 34 | $628 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $304 |
| Ciprofloxacin Hcl | 37 | $171 |
| Oxybutynin Chloride | 12 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $52 | $123,484101 claims |
| Astellas Pharma US IncMyrbetriq | $113 | $82,51188 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 250 urology providers in Missouri.
Other urology in Kansas City
- Samuel KuykendallKansas City$141K
- Donald NeffKansas City$27K
- Lukas HockmanKansas City$14K
- Patrick ProbstKansas City$14K
- Travis BullockSaint Louis$201K
- Michael JohnsonSaint Louis$160K
- Gerald ParkNorth Kansas City$136K
- Gurdarshan SandhuSaint Louis$101K
- Etai GoldenbergSt. Louis$95K
- Gregory McLennanSaint Louis$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.